Supercharged immune cells take on tough lymphomas
NCT ID NCT02690545
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment involves taking a patient's own T cells (a type of immune cell), adding a gene that helps them recognize and attack lymphoma cells carrying the CD30 protein, and infusing them back after chemotherapy. The goal is to find a safe dose and see how many patients remain cancer-free for two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD30-targeting CAR T-cells (ATLCAR.CD30 cells)
What this could lead to
If it works, this could offer a new treatment option for patients with hard-to-treat lymphomas that have not responded to other therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 38 participants, so results may not apply broadly. The engineered T cells may not last long in the body, and there are risks of serious side effects including life-threatening reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.